Clinical Trials | November 03, 2022
SRL Diagnostics inaugurates an upgraded laboratory at Gurugram
The laboratory is equipped to perform high-volume diagnostic testing services
The laboratory is equipped to perform high-volume diagnostic testing services
The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.
Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
Revenue from operations up 26% to Rs. 768 crores
The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.
Subscribe To Our Newsletter & Stay Updated
